PB1719: NIRAPARIB IN B-CELL LYMPHOID MALIGNANCIES: EXPLORING SYNTHETIC LETHALITY AS TARGET FOR THERAPY
Beatriz Lapa,
Ana Patrícia Portelinha,
Maria Inês Costa,
Joana Jorge,
Raquel Alves,
Ana Bela Sarmento-Ribeiro,
Ana Cristina Gonçalves
Affiliations
Beatriz Lapa
1 Faculty of Medicine (FMUC), University of Coimbra, Laboratory of Oncobiology and Hematology (LOH) and University Clinic of Hematology and Oncology, Coimbra, Portugal
Ana Patrícia Portelinha
1 Faculty of Medicine (FMUC), University of Coimbra, Laboratory of Oncobiology and Hematology (LOH) and University Clinic of Hematology and Oncology, Coimbra, Portugal
Maria Inês Costa
1 Faculty of Medicine (FMUC), University of Coimbra, Laboratory of Oncobiology and Hematology (LOH) and University Clinic of Hematology and Oncology, Coimbra, Portugal
Joana Jorge
1 Faculty of Medicine (FMUC), University of Coimbra, Laboratory of Oncobiology and Hematology (LOH) and University Clinic of Hematology and Oncology, Coimbra, Portugal
Raquel Alves
1 Faculty of Medicine (FMUC), University of Coimbra, Laboratory of Oncobiology and Hematology (LOH) and University Clinic of Hematology and Oncology, Coimbra, Portugal
Ana Bela Sarmento-Ribeiro
1 Faculty of Medicine (FMUC), University of Coimbra, Laboratory of Oncobiology and Hematology (LOH) and University Clinic of Hematology and Oncology, Coimbra, Portugal
Ana Cristina Gonçalves
1 Faculty of Medicine (FMUC), University of Coimbra, Laboratory of Oncobiology and Hematology (LOH) and University Clinic of Hematology and Oncology, Coimbra, Portugal
